Alnylam Pharmaceuticals Inc (ALNY) Event July 28, 2022, 00:00 UTC (66% Neutral) ALNYLAM PHARMACEUTICALS, INC. (ALNY) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 9:06 a.m. 🏢 Alnylam Pharmaceuticals Inc (ALNY) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-07-28 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-389.85M $-517.74M $127.89M +24.70% 📉 Total Assets $3.64B $3.33B $312.89M +9.39% 📈 Total Liabilities $3.06B $3.15B $-99.28M -3.15% ↘️ Stockholders' Equity $-36.08M $249.00K $-36.33M -14590.36% 📉 Operating Income/Loss $-332.41M $-338.42M $6.00M +1.77% ↗️ R&D Expense $26.23M $970.00K $25.26M +2604.54% 📉 SG&A Expense $292.18M $324.45M $-32.27M -9.95% 📈 Revenues $63.10M $9.30M $53.80M +578.49% 📈 Earningspersharebasic $-3.32 $-4.29 $0.97 +22.61% 📈 Earningspersharediluted $-3.32 $-4.29 $0.97 +22.61% 📈 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Alnylam Pharmaceuticals Inc (ALNY) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document